Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Alexandre Biasi Cavalcanti, Fernando G Zampieri, Régis Goulart Rosa, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 21, pp. 2041-2052
Open Access | Times Cited: 1072

Showing 1-25 of 1072 citing articles:

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2022) Vol. 145, Iss. 8
Open Access | Times Cited: 4140
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2023) Vol. 147, Iss. 8
Open Access | Times Cited: 3999
Severe Covid-19
David Berlin, Roy M. Gulick, Fernando J. Martínez
New England Journal of Medicine (2020) Vol. 383, Iss. 25, pp. 2451-2460
Closed Access | Times Cited: 1390
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen, Ajay Nirula, Barry N. Heller, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 3, pp. 229-237
Open Access | Times Cited: 1347
Cross Mark Policy

(2022)
Open Access | Times Cited: 1336
Mild or Moderate Covid-19
Rajesh T. Gandhi, John B. Lynch, Carlos del Rı́o
New England Journal of Medicine (2020) Vol. 383, Iss. 18, pp. 1757-1766
Closed Access | Times Cited: 1274
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby, Marion Mafham, Louise Linsell, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 21, pp. 2030-2040
Open Access | Times Cited: 1175
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 734
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Luca Perico, Ariela Benigni, Federica Casiraghi, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 1, pp. 46-64
Open Access | Times Cited: 561
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531
Immunopathology of Hyperinflammation in COVID-19
Joshua Gustine, Dennis Jones
American Journal Of Pathology (2020) Vol. 191, Iss. 1, pp. 4-17
Open Access | Times Cited: 480
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado, et al.
The Lancet (2021) Vol. 397, Iss. 10291, pp. 2253-2263
Open Access | Times Cited: 448
Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19
Ning Rosenthal, Zhun Cao, Jake Gundrum, et al.
JAMA Network Open (2020) Vol. 3, Iss. 12, pp. e2029058-e2029058
Open Access | Times Cited: 444
The first 12 months of COVID-19: a timeline of immunological insights
Thiago de Amorim Carvalho, Florian Krammer, Akiko Iwasaki
Nature reviews. Immunology (2021) Vol. 21, Iss. 4, pp. 245-256
Open Access | Times Cited: 423
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1382-1392
Open Access | Times Cited: 405
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19
Wesley H. Self, Matthew W. Semler, Lindsay Leither, et al.
JAMA (2020) Vol. 324, Iss. 21, pp. 2165-2165
Open Access | Times Cited: 401
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane Cordeiro Veiga, João Antônio Gonçalves Garreta Prats, Danielle Leão Cordeiro de Farias, et al.
BMJ (2021), pp. n84-n84
Open Access | Times Cited: 382
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
Remo H.M. Furtado, Otávio Berwanger, Henrique Fonseca, et al.
The Lancet (2020) Vol. 396, Iss. 10256, pp. 959-967
Open Access | Times Cited: 360
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update
Waleed Alhazzani, Laura Evans, Fayez Alshamsi, et al.
Critical Care Medicine (2021) Vol. 49, Iss. 3, pp. e219-e234
Open Access | Times Cited: 360
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19
Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, et al.
JAMA (2021) Vol. 325, Iss. 3, pp. 254-254
Open Access | Times Cited: 335
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu E. Rebeaud, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 1, pp. 19-27
Open Access | Times Cited: 295
COVID‐19 in Nursing Homes: Calming the Perfect Storm
Joseph G. Ouslander, David C. Grabowski
Journal of the American Geriatrics Society (2020) Vol. 68, Iss. 10, pp. 2153-2162
Open Access | Times Cited: 292
COVID-19 and Solid Organ Transplantation: A Review Article
Yorg Azzi, Rachel Bartash, Joseph R. Scalea, et al.
Transplantation (2020) Vol. 105, Iss. 1, pp. 37-55
Open Access | Times Cited: 286
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher Butler, Jienchi Dorward, Ly‐Mee Yu, et al.
The Lancet (2021) Vol. 397, Iss. 10279, pp. 1063-1074
Open Access | Times Cited: 272
Page 1 - Next Page

Scroll to top